Related Experiment Video
Updated: Jun 27, 2026
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1
Mark W Veldman1, Carl C Reading, Michael A Farrell
1Department of Radiology, Mayo Clinic, 200 1st St., SW, Rochester, MN 55902, USA.
AJR. American Journal of Roentgenology
|November 21, 2008
Abstract
Objective:
The objective of our study was to show the efficacy and safety of percutaneous ethanol ablation in managing recurrent primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1 (MEN1) after subtotal parathyroidectomy.
Conclusion:
Ethanol ablation is a viable alternative to reoperation for the management of recurrent primary hyperparathyroidism in patients with MEN1.
